<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-137847" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Anubhav</given-names>
          </name>
          <aff>Mclaren Hopsital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zahra</surname>
            <given-names>Farah</given-names>
          </name>
          <aff>Northwestern Mchenry/RFMUS</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anubhav Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Farah Zahra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-137847.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Transthyretin amyloid cardiomyopathy is a rare but severe cause of restrictive cardiomyopathy caused by the accumulation of transthyretin fibrils in the myocardium. It can present with new or worsening heart failure or new conduction system disease. Due to the lack of knowledge and efficient diagnostic modalities, this disease was often missed in clinical settings. However, with the advent of contemporary cardiac imaging techniques and effective therapeutic options, early diagnosis and treatment are possible. This activity reviews the pathophysiology, diagnosis, and treatment of Transthyretin amyloid cardiomyopathy and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the epidemiology of transthyretin amyloid cardiomyopathy. .</p></list-item><list-item><p>Explain the common cardiac and non-cardiac findings associated with transthyretin amyloid cardiomyopathy.</p></list-item><list-item><p>Describe the typical imaging findings associated with transthyretin amyloid cardiomyopathy.</p></list-item><list-item><p>Outline the available treatment options for transthyretin amyloid cardiomyopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137847">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-137847.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is one of the types of systemic amyloidosis in which misfolded transthyretin (TTR) protein gets deposited in the myocardium. Another pertinent etiology of cardiac amyloidosis is due to the deposition of&#x000a0;immunoglobulin light-chain (AL) aggregates. Several other amyloidogenic proteins may get deposited in various organs and tissues but rarely involve the myocardium.<xref ref-type="bibr" rid="article-137847.r1">[1]</xref></p>
        <p>Transthyretin amyloidosis (ATTR) is a systemic disease. Due to amyloid deposition in extracardiac tissues, patients often have associated extracardiac signs and symptoms. However, isolated cardiac involvement has been reported as well.<xref ref-type="bibr" rid="article-137847.r2">[2]</xref>&#x000a0;Diagnosis of ATTR-CM was often missed or delayed due to previously lacking optimal diagnostic modalities. ATTR-CM often progresses to advanced stages with minimal clinical signs and symptoms initially and is therefore associated with poor prognosis.<xref ref-type="bibr" rid="article-137847.r3">[3]</xref></p>
        <p>With improving bone avid radiotracer scintigraphy technology and the advent of new therapeutic options, diagnosis and treatment of ATTR-CM have become possible. As diagnostic capabilities are getting better, studies have shown a higher prevalence of ATTR-CM in patients with heart failure with preserved ejection fraction than previously perceived.<xref ref-type="bibr" rid="article-137847.r4">[4]</xref></p>
      </sec>
      <sec id="article-137847.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Transthyretin (previously known as prealbumin) is a normal circulating protein that functions as a carrier protein for retinol (vitamin A) and thyroxine. It is primarily synthesized by the liver (&#x0003e;95%). Additionally, in small amounts, it is also produced in the choroid plexus and retinal epithelium.<xref ref-type="bibr" rid="article-137847.r5">[5]</xref><xref ref-type="bibr" rid="article-137847.r6">[6]</xref>&#x000a0;Usually, it circulates in a tetrameric form composed of 4 beta-sheet-rich monomers. However, structural changes in the TTR protein can cause it to misfold and lose the tetrameric form, causing it to aggregate and deposit in various tissues. The myocardium and peripheral nerves are the most common sites for the deposition of misfolded&#x000a0;TTR protein.<xref ref-type="bibr" rid="article-137847.r7">[7]</xref>&#x000a0;The clinical phenotype of ATTR depends on the type and extent of tissue involvement.<xref ref-type="bibr" rid="article-137847.r8">[8]</xref></p>
        <p>Chromosome 18 carries the gene for&#x000a0;TTR protein. Therefore, a mutation in the gene coding for TTR can cause structural changes in TTR, causing it to misfold. This type of ATTR is referred to as hereditary transthyretin amyloid (hATTR). In addition, it has been observed that the normal aging process can render ATTR tetramer prone to misfolding, even when the genetic sequence of the TTR is expected.<xref ref-type="bibr" rid="article-137847.r3">[3]</xref>&#x000a0;This type of ATTR is&#x000a0;referred to as wild-type transthyretin amyloid (wATTR).<xref ref-type="bibr" rid="article-137847.r9">[9]</xref></p>
        <p>Myocardial deposition of&#x000a0;misfolded&#x000a0;TTR protein in both types of ATTR (hATTR and wATTR) causes a clinical phenotype of transthyretin amyloid cardiomyopathy (ATTR-CM). However, emerging clinical data have&#x000a0;shown that wATTR-CM is&#x000a0;more common than hATTR.<xref ref-type="bibr" rid="article-137847.r10">[10]</xref><xref ref-type="bibr" rid="article-137847.r11">[11]</xref></p>
      </sec>
      <sec id="article-137847.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence data of ATTR-CM is&#x000a0;limited and not well characterized.<xref ref-type="bibr" rid="article-137847.r12">[12]</xref>&#x000a0;Limited data is due to missed and delayed diagnosis in most patients, because of&#x000a0;heterogenous clinical presentation, and majorly due to previously lacking sensitive diagnostic modality. With recent advancements in nuclear cardiac imaging with technetium pyrophosphate scan, the diagnosis of ATTR-CM is possible without cardiac biopsy. Therefore, more patients are being screened and diagnosed with ATTR-CM.<xref ref-type="bibr" rid="article-137847.r13">[13]</xref>&#x000a0;At the same time, survival has improved, increasing its prevalence. As a result, 5,000&#x000a0;to 7,000 new cases are identified annually in the United States.&#x000a0;Recent studies suggest a prevalence rate of approximately 20% in a cohort with heart failure (HF) with increased myocardial wall thickening of more than 14 mm.<xref ref-type="bibr" rid="article-137847.r14">[14]</xref><xref ref-type="bibr" rid="article-137847.r15">[15]</xref>&#x000a0;Thus, the prevalence is increasing as survival has improved dramatically.</p>
        <p>wATTR-CM is the more common type of ATTR-CM. It is primarily seen in older patients and has a male predominance.<xref ref-type="bibr" rid="article-137847.r10">[10]</xref><xref ref-type="bibr" rid="article-137847.r11">[11]</xref>&#x000a0;Several autopsy studies have shown that the incidence of wATTR deposits increases with&#x000a0;advancing age.<xref ref-type="bibr" rid="article-137847.r16">[16]</xref><xref ref-type="bibr" rid="article-137847.r17">[17]</xref>&#x000a0;It is often seen in conjunction with other cardiac diseases associated with aging, like aortic stenosis, atrial fibrillation, and heart failure with preserved ejection fraction (HFpEF).<xref ref-type="bibr" rid="article-137847.r17">[17]</xref><xref ref-type="bibr" rid="article-137847.r18">[18]</xref><xref ref-type="bibr" rid="article-137847.r19">[19]</xref>&#x000a0;A recent community-based cohort study reported a substantial prevalence of&#x000a0;ATTR-CM in older male patients with HFpEF&#x000a0;and left ventricular hypertrophy (LVH).<xref ref-type="bibr" rid="article-137847.r4">[4]</xref></p>
        <p>The lower prevalence of wATTR in females may partly&#x000a0;be understood by the hypothesized cardioprotective effect of estrogen and possible underdiagnosis due to smaller heart size in females not meeting the screening threshold for ATTR-CM.&#x000a0;Compared to wATTR, hATTR is more equally distributed among males and females. However, clinical expression is still more common in males.<xref ref-type="bibr" rid="article-137847.r20">[20]</xref>&#x000a0;In a pooled analysis from 69 studies and 4669 patients with ATTR-CM, 17% were females, and 83% were men. Studies of wATTR had the lowest proportion&#x000a0;of&#x000a0;females (9%), whereas hATTR had the highest (29%).<xref ref-type="bibr" rid="article-137847.r21">[21]</xref></p>
        <p>The TTR gene is present on chromosome 18. hATTR follows an autosomal dominant inheritance pattern. However, disease penetrance is more complicated and less understood. The age of onset of clinical disease in hATTR-CM varies widely and depends on the type of mutation.&#x000a0;More than 100 different TTR mutations have been identified. These mutations have varied geographical distribution. The most common mutation in the USA is Val122lle. It is&#x000a0;seen in approximately 3 to 4% of African Americans, with 1.5 million carriers. The most common mutation in the rest of the world is Val30Met.<xref ref-type="bibr" rid="article-137847.r22">[22]</xref></p>
      </sec>
      <sec id="article-137847.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Misfolded&#x000a0;TTR protein forms insoluble fibers. In the heart, they occupy interstitial spaces in the myocardium, making it stiff and rigid. TTR deposition causes further&#x000a0;myocardial fibrosis and eventually affects its mechanical function. Due to TTR deposition, the myocardium appears thickened and hypertrophied on cardiac imaging. Compromise in ventricular compliance initially causes diastolic dysfunction. In advanced stages, myocardial dysfunction can result in globally reduced systolic dysfunction.<xref ref-type="bibr" rid="article-137847.r23">[23]</xref></p>
        <p>Diastolic dysfunction causes an increase in left ventricular end-diastolic pressure and left atrial pressures. Persistently&#x000a0;increased left atrial pressures and left atrial dilatation increased the likelihood of developing atrial arrhythmias in these patients. Myocardial infiltration often affects the electrical conduction system as well.<xref ref-type="bibr" rid="article-137847.r24">[24]</xref>&#x000a0;Ventricular arrhythmias have been reported in ATTR-CM but are significantly less common than AL cardiomyopathy.<xref ref-type="bibr" rid="article-137847.r25">[25]</xref>&#x000a0;The lower frequency of ventricular arrhythmias might be explained due to the direct cardiotoxic effect of light chain protein.<xref ref-type="bibr" rid="article-137847.r26">[26]</xref></p>
        <p>The autonomic and peripheral nervous systems are common extra-cardiac sites for misfolded&#x000a0;TTR protein deposition. It is seen that hATTR affects the nervous system more commonly, whereas cardiomyopathy is more commonly seen with wATTR-CM.<xref ref-type="bibr" rid="article-137847.r10">[10]</xref><xref ref-type="bibr" rid="article-137847.r11">[11]</xref></p>
      </sec>
      <sec id="article-137847.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Endomyocardial biopsy with congo red staining remains the gold standard to diagnose ATTR-CM.<xref ref-type="bibr" rid="article-137847.r27">[27]</xref>&#x000a0;The sensitivity and specificity reach up to 100% if a biopsy specimen is grabbed from greater than or equal to 4 intracardiac sites. However, the sensitivity of extracardiac tissue biopsy varies significantly and is usually not recommended, especially with the wATTR disease process.<xref ref-type="bibr" rid="article-137847.r28">[28]</xref>&#x000a0;In experimental labs, immunochemistry and tandem mass spectroscopy can be used to identify the type and nature of misfolded precursor protein.<xref ref-type="bibr" rid="article-137847.r29">[29]</xref></p>
        <p>With the advent of cardiac technetium pyrophosphate scan and cardiac MRI, the need for tissue diagnosis has limited clinical significance.</p>
      </sec>
      <sec id="article-137847.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>ATTR-CM typically presents with clinical signs and symptoms of progressive congestive heart failure. In addition, they often have cardiac arrhythmia and conduction system disease, which may occur years before the development of heart failure.<xref ref-type="bibr" rid="article-137847.r30">[30]</xref></p>
        <p>hATTR can have a variable presentation. It can present as primary cardiomyopathy or primary autonomic or peripheral neuropathy. Not uncommonly, it can present mixed clinical features of both cardiomyopathy and neuropathy.<xref ref-type="bibr" rid="article-137847.r31">[31]</xref>&#x000a0;The age of onset of clinical disease is also variable&#x000a0;and depends on the type of mutation.<xref ref-type="bibr" rid="article-137847.r32">[32]</xref>&#x000a0;Comparatively, the clinical&#x000a0;course&#x000a0;of wATTR follows a&#x000a0;more consistent&#x000a0;pattern.<xref ref-type="bibr" rid="article-137847.r11">[11]</xref><xref ref-type="bibr" rid="article-137847.r23">[23]</xref><xref ref-type="bibr" rid="article-137847.r33">[33]</xref>&#x000a0;Comparatively, polyneuropathy is more familiar&#x000a0;in hATTR than wATTR.&#x000a0;Both conduction system disease and arrhythmias are more common with wATTR than hATTR.<xref ref-type="bibr" rid="article-137847.r34">[34]</xref></p>
        <p>
<bold>Congestive Heart Failure</bold>
</p>
        <p>ATTR-CM&#x000a0;should be suspected&#x000a0;in old patients with recurrent HF exacerbations, irrespective of their ejection fraction status. Often, they will have fatigue, poor exercise tolerance, and shortness of breath with the New York Heart Association (NYHA) functional class II to IV. In addition, it is seen that they have significant right ventricular involvement, causing peripheral congestive symptoms like elevated jugular venous pressure, lower extremity edema, hepatic congestion, and ascites. Often, at advanced stages, cardiorenal syndrome ensues. Interestingly, these patients often develop intolerance to beta-blockers and angiotensin convertase enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), which they might have tolerated previously.<xref ref-type="bibr" rid="article-137847.r35">[35]</xref></p>
        <p>
<bold>Cardiac Arrhythmias</bold>
</p>
        <p>Atrial fibrillation is the most common cardiac arrhythmia seen in ATTR-CM. It is present in 40&#x000a0;to 60% of patients at the time of diagnosis. Eventually, all patients develop atrial fibrillation during the disease. When present, it is usually of persistent type.<xref ref-type="bibr" rid="article-137847.r36">[36]</xref>&#x000a0;Not uncommonly,&#x000a0;non-sustained ventricular tachycardia is also seen.<xref ref-type="bibr" rid="article-137847.r37">[37]</xref><xref ref-type="bibr" rid="article-137847.r24">[24]</xref>&#x000a0;Atrial fibrillation is&#x000a0;poorly tolerated in this population due to the diastolic dysfunction and the restrictive nature of ATTR-CM. In&#x000a0;atrial fibrillation, patients are often symptomatic and might experience significant shortness of breath, palpitation, and hypotension, even at a slower ventricular rate. In addition, they often present with frequent heart failure exacerbation.<xref ref-type="bibr" rid="article-137847.r24">[24]</xref>&#x000a0;Not uncommonly, patients may present with stroke or systemic embolization due to undiagnosed atrial fibrillation. In addition, all patients with ATTR-CM are at increased risk of forming intracardiac thrombus irrespective of their rhythm status.<xref ref-type="bibr" rid="article-137847.r38">[38]</xref></p>
        <p>
<bold>Conduction System Disease</bold>
</p>
        <p>Deposition of TTR amyloid in interstitial space disrupts the normal conduction system of the heart. Patients may present with varying degrees of heart block due to the involvement of atrioventricular (AV) nodal and infra AV nodal conduction. Due to associated conduction system disease, atrial fibrillation usually presents with a slow or controlled ventricular response. Patients will&#x000a0;give a history of lightheadedness, presyncope, and unexplained falls. Elevated jugular venous distension with cannon A wave can be seen when the patient is in complete heart block due to AV dissociation.&#x000a0;Eventually, one out of every three patients with wATTR-CM patients ends up requiring permanent pacemaker (PPM) implantation.<xref ref-type="bibr" rid="article-137847.r30">[30]</xref><xref ref-type="bibr" rid="article-137847.r33">[33]</xref></p>
        <p>
<bold>Extracardiac Manifestations</bold>
</p>
        <p>Extracardiac TTR amyloid deposition can cause nerve entrapment in close spaces. Bilateral carpal tunnel syndrome (CTS) and lumbar spinal stenosis are commonly seen with the ATTR disease process.<xref ref-type="bibr" rid="article-137847.r16">[16]</xref>&#x000a0;More than half of wATTR-CM patients initially present with bilateral CTS.<xref ref-type="bibr" rid="article-137847.r11">[11]</xref>&#x000a0;When present, CTS usually occurs 5-10 years before&#x000a0;the development of overt wATTR-CM.<xref ref-type="bibr" rid="article-137847.r39">[39]</xref>&#x000a0;Lumbar spinal stenosis occurs due to TTR deposition in ligamentum flavum causing spinal foraminal narrowing.<xref ref-type="bibr" rid="article-137847.r40">[40]</xref>&#x000a0;Tendinopathies and spontaneous tendon ruptures are not uncommon. A retrospective study showed that 33% of wATTR-CM patients had spontaneous rupture&#x000a0;of the distal biceps tendon.<xref ref-type="bibr" rid="article-137847.r41">[41]</xref>&#x000a0;Autonomic neuropathy may manifest as orthostatic hypotension, erectile dysfunction, dyshidrosis, or gastrointestinal motility issues. "Natural cure of blood pressure" or intolerance of blood pressure-lowering medications, especially beta-blockers and ACEi/ARB, is in part related to autonomic dysregulation. Both autonomic and peripheral neuropathies are more common in hATTR than wATT.<xref ref-type="bibr" rid="article-137847.r3">[3]</xref></p>
        <p>Clinical suspicion for ATTR-CM should be heightened, especially when cardiac and extracardiac findings are seen simultaneously.</p>
      </sec>
      <sec id="article-137847.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Electrocardiogram (ECG)</bold>
</p>
        <p>Electrocardiogram (ECG) of ATTR-CM is described to have low voltage ECG patterns along&#x000a0;with poor R wave progression across the precordial leads.<xref ref-type="bibr" rid="article-137847.r42">[42]</xref>&#x000a0;More commonly, the presence of Q waves unrelated to prior myocardial infarction (pseudo-infarct pattern) has also been reported.<xref ref-type="bibr" rid="article-137847.r31">[31]</xref>&#x000a0;Thus, the presence of low voltage ECG disproportionate to the LV wall thickness may help to differentiate ATTR-CM from other causes of left ventricular hypertrophy (LVH), like hypertensive heart disease and hypertrophic cardiomyopathies.&#x000a0;</p>
        <p>However, these ECG findings are not acceptably sensitive.<xref ref-type="bibr" rid="article-137847.r35">[35]</xref>&#x000a0;They&#x000a0;can aid with the diagnosis but should not be used as a screening tool.<xref ref-type="bibr" rid="article-137847.r43">[43]</xref>&#x000a0;Only 25 to 40% of patients with ATTR-CM may have low voltage ECG.<xref ref-type="bibr" rid="article-137847.r30">[30]</xref>&#x000a0;Moreover, the sensitivity of ECG is highly dependent on the definition used to describe the criteria for low voltage.<xref ref-type="bibr" rid="article-137847.r44">[44]</xref>&#x000a0;A high&#x000a0;voltage QRS pattern ECG has been reported in the Val122Ile variant of hATTR.<xref ref-type="bibr" rid="article-137847.r45">[45]</xref>&#x000a0;Therefore, the presence of LVH on ECG does not exclude ATTR-CM.</p>
        <p>
<bold>Echocardiogram</bold>
</p>
        <p>Myocardial infiltration of ATTR causes concentric bi-ventricular hypertrophy. A&#x000a0;septal wall thickness of &#x0003e;12 mm should heighten clinical suspicion but is not diagnostic.<xref ref-type="bibr" rid="article-137847.r46">[46]</xref>&#x000a0;Due to infiltration, the myocardium is more&#x000a0;echogenic compared to that seen in ventricular hypertrophy. It is often referred to as a "granular sparkling appearance."<xref ref-type="bibr" rid="article-137847.r3">[3]</xref>&#x000a0;Small LV cavity size, biatrial enlargement, thickened interatrial septal, and thickened valves are other structural abnormalities that are commonly seen. Diastolic dysfunction with a restrictive flow pattern is frequently seen on the Doppler exams. Due to increased pressure in the left atrium, restrive flow pattern through the mitral valve, and the irregular atrial endocardial surface because of amyloid deposition, the left atrium is prone to form thrombus even in the absence of atrial arrhythmias.<xref ref-type="bibr" rid="article-137847.r47">[47]</xref></p>
        <p>Strain echocardiography has emerged as a practical tool in the early detection of cardiac amyloidosis. "Apical sparing" with progressive worsening of longitudinal strain when moving to the midventricular and basal segment is characteristic of cardiac amyloidosis. It gives an appearance of a "bulls-eye pattern," sometimes referred to as "cherry on top" in the strain imaging. The apical to basal strain ratio and apical to mid-ventricular plus basal strain have shown good diagnostic accuracy.<xref ref-type="bibr" rid="article-137847.r47">[47]</xref></p>
        <p>Echocardiographic parameters can help identify patients with cardiac amyloidosis but cannot be used to differentiate between hATTR, wATTR, or AL type.<xref ref-type="bibr" rid="article-137847.r48">[48]</xref></p>
        <p>
<bold>Cardiac Magnetic Resonance Imaging (CMR)&#x000a0;</bold>
</p>
        <p>Cardiac magnetic resonance imaging (CMR) has considerable utility as both a screening tool and a tool to track treatment response.<xref ref-type="bibr" rid="article-137847.r35">[35]</xref>&#x000a0;CMR with late gadolinium enhancement (CMR-LGE) can detect extracellular deposits of amyloid. The presence of diffuse transmural or subendocardial deposits can diagnose amyloidosis with a sensitivity and specificity of 85 to 90%.<xref ref-type="bibr" rid="article-137847.r49">[49]</xref>&#x000a0;The inability to "null" or suppress the myocardial signal on phase-sensitive inversion recovery (PSIR) imaging of an LGE scan is also diagnostic.<xref ref-type="bibr" rid="article-137847.r50">[50]</xref></p>
        <p>It is seen that T1 signals are amplified in cardiac amyloidosis, similar to&#x000a0;post-contrast extracellular volume fraction (ECV). CMR with parametric imaging can identify native (non-contrast) myocardial T1 signal and ECV. Parametric imaging is believed to be a more sensitive and reliable measure of amyloid burden and, therefore, can be used for treatment tracking.<xref ref-type="bibr" rid="article-137847.r50">[50]</xref><xref ref-type="bibr" rid="article-137847.r51">[51]</xref></p>
        <p>CMR cannot reliably differentiate between hATTR, wATTR, or AL type.<xref ref-type="bibr" rid="article-137847.r52">[52]</xref></p>
        <p>
<bold>Nuclear Imaging&#x000a0;</bold>
</p>
        <p>Nuclear imaging using avid bone radiotracers is the sole imaging modality available that can accurately diagnose ATTR-CM without the need for a biopsy. There are&#x000a0;majorly three&#x000a0;types of bone avid radiotracers that are available. The most commonly used is technetium pyrophosphate (TC-PYP) (available in the USA). Other available radiotracers are&#x000a0;Tc-DPD and Tc-HMDP (available in Europe).<xref ref-type="bibr" rid="article-137847.r3">[3]</xref></p>
        <p>During the scan, TC-PYP is injected intravenously. Once in circulation, it selectively binds to osseous tissue and ATTR fibrils.<xref ref-type="bibr" rid="article-137847.r32">[32]</xref>&#x000a0;A possible mechanism of myocardial retention of TC-PYP could be&#x000a0;due&#x000a0;to the microcalcifications associated with ATTR cardiomyopathy.<xref ref-type="bibr" rid="article-137847.r53">[53]</xref>&#x000a0;Myocardial uptake of TC-PYP is visually graded compared to the bone update of the ribs to get a semiquantitative scheme.<xref ref-type="bibr" rid="article-137847.r54">[54]</xref></p>
        <table-wrap id="article-137847.table0" position="float" orientation="portrait">
          <table style="width: 282px;" border="1" cellspacing="1" cellpadding="15">
            <tbody>
              <tr style="height: 14.5px;">
                <td style="width: 74.4062px; height: 14.5px;" rowspan="1" colspan="1">Grade 0</td>
                <td style="width: 341.594px; height: 14.5px;" rowspan="1" colspan="1">No Myocardial Update</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 74.4062px; height: 13px;" rowspan="1" colspan="1">Grade 1</td>
                <td style="width: 341.594px; height: 13px;" rowspan="1" colspan="1">Myocardial update &#x0003c; Bone&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 74.4062px; height: 13px;" rowspan="1" colspan="1">Grade 2</td>
                <td style="width: 341.594px; height: 13px;" rowspan="1" colspan="1">Myocardial update = Bone</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 74.4062px; height: 13px;" rowspan="1" colspan="1">Grade 3</td>
                <td style="width: 341.594px; height: 13px;" rowspan="1" colspan="1">Myocardial update &#x0003e; Bone&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>TC-PYP scan offers few advantages over other imaging modalities. TC-PYP scan can detect ATTR deposition in the myocardium much earlier than the development of structural and&#x000a0;conduction system changes. TC-PYP scan can diagnose ATTR-CM with 100% specificity without the need for biopsy when a grade 2 or 3 update is present, and there are no monoclonal proteins on urine and serum testing.<xref ref-type="bibr" rid="article-137847.r13">[13]</xref>&#x000a0;Quantitative comparison of radiotracer uptake of the heart and contralateral chest can help to differentiate ATTR from AL cardiac amyloid. A heart to the contralateral chest uptake ratio of 1.5 or greater suggests ATTR presence.<xref ref-type="bibr" rid="article-137847.r55">[55]</xref>&#x000a0;This ratio has also demonstrated a prognosticating value. ATTR-CM patients with a ratio of 1.6 or greater have the&#x000a0;worst&#x000a0;5-year outcomes&#x000a0;&#x000a0;</p>
        <p>The specificity of the TC-PYP scan to differentiate ATTR from AL does reduce when monoclonal proteins are present. 40% to 50% of patients with ATTR were found to have coexisting unrelated monoclonal gammopathy.<xref ref-type="bibr" rid="article-137847.r56">[56]</xref>&#x000a0;In these cases, a myocardial biopsy might be necessary to diagnose ATTR-CM.<xref ref-type="bibr" rid="article-137847.r35">[35]</xref></p>
        <p>
<bold>Genetic Testing&#x000a0;</bold>
</p>
        <p>Genetic testing may be&#x000a0;obtained once the diagnosis of ATTR-CM is confirmed (either with nuclear imaging or with cardiac biopsy). Genetic testing will help to differentiate hATTR-CM from wATTR-CM. In addition, differentiating between hATTR-CM from Wt-ATTR-CM might be needed to accommodate disease-specific treatment.<xref ref-type="bibr" rid="article-137847.r57">[57]</xref></p>
      </sec>
      <sec id="article-137847.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Supportive Treatment of Cardiac Involvement</bold>
</p>
        <p>
<bold>Management of Heart Failure</bold>
</p>
        <p>Dietary sodium restriction and diuretic use are essential to maintain euvolemia in ATTR-CM patients. Achieving and maintaining euvolemia is often challenging in these patients due to the small LV cavity and autonomic dysfunction.&#x000a0;Loop diuretics with higher oral bioavailability (e.g., torsemide and bumetanide) are often preferred in combination with aldosterone receptor blockers. Beta-blockers and&#x000a0;ACE, ARBs, or angiotensin receptor-neprilysin inhibitors (ARNi) therapies are usually not well tolerated because of ensuing hypotension due to the reasons mentioned above. With the progression of ATTR-CM and reduction of LV cavity size, stroke volume, and cardiac output reduce, resulting in a reduction in renal perfusion, causing cardio-renal syndrome.<xref ref-type="bibr" rid="article-137847.r58">[58]</xref>&#x000a0;In advanced cases, midodrine and compression stockings may be used. Verapamil (non-dihydropyridine calcium channel blockers) should be avoided due to reports of worsening hypotension and conduction system problems.<xref ref-type="bibr" rid="article-137847.r59">[59]</xref></p>
        <p>
<bold>Management of Arrhythmias</bold>
</p>
        <p>ATTR-CM patients have a narrow&#x000a0;scope of heart rate variability.&#x000a0;Extreme tachycardia and bradycardia are poorly tolerated due to the small LV cavity,&#x000a0;high-grade diastolic dysfunction, and low stroke volume. Similarly, atrial contraction (often called&#x000a0;"atrial kick") is crucial in ventricular filling. Therefore, rhythm control is the preferred strategy for managing atrial fibrillation. Rhythm control can be achieved by antiarrhythmics or&#x000a0;by catheter ablation. Amiodarone is the preferred&#x000a0;agent when using antiarrhythmics due to its better safety profile when dealing with cardiomyopathy and some clinical data demonstrating&#x000a0;its safety in ATTR-CM.<xref ref-type="bibr" rid="article-137847.r36">[36]</xref>&#x000a0;However, these patients are at increased risk of developing intracardiac thrombus even when receiving&#x000a0;anticoagulant therapy.<xref ref-type="bibr" rid="article-137847.r60">[60]</xref>&#x000a0;Therefore, all ATTR-CM patients&#x000a0;with atrial fibrillation should be on life-long anticoagulation irrespective of their&#x000a0;CHADs-VASc score.</p>
        <p>A significant percentage of ATTR-CM patients develop conduction system disease, eventually requiring permanent pacemaker support.<xref ref-type="bibr" rid="article-137847.r30">[30]</xref>&#x000a0;When&#x000a0;symptoms of palpitations, presyncope, or frank syncope are reported, Holter or event monitoring must be considered. When indicated, permanent pacing should&#x000a0;be done per ACC/AHA/HRS&#x000a0;guidelines.<xref ref-type="bibr" rid="article-137847.r61">[61]</xref>&#x000a0;In pacemaker-dependent patients with advanced disease who have recurrent heart failure exacerbation or have low systemic blood pressure, a lower rate limit for pacing can be increased to improve their cardiac output. Bi-ventricular pacing is often considered when significant ventricular dys-synchrony develops due to chronic right ventricular pacing. Implantable cardioverter-defibrillator (ICD) should only be used for secondary prevention and follow&#x000a0;ACC/AHA/HRS&#x000a0;guidelines. There is no clear data on ICD use for primary prevention in cardiac amyloidosis.<xref ref-type="bibr" rid="article-137847.r62">[62]</xref><xref ref-type="bibr" rid="article-137847.r63">[63]</xref></p>
        <p>
<bold>Therapies Targeting&#x000a0;Transthyretin</bold>
</p>
        <p>Currently, three major pharmacological strategies are being studied to specifically target ATTR-CM.<xref ref-type="bibr" rid="article-137847.r3">[3]</xref>&#x000a0;These are summarized in the table below.&#x000a0;</p>
        <table-wrap id="article-137847.table1" position="float" orientation="portrait">
          <table style="height: 224px; width: 467px;" border="1" cellspacing="1" cellpadding="8">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 292.773px; height: 13px;" rowspan="1" colspan="1">
<bold>Mechanism of action</bold>
</td>
                <td style="width: 125.226px; height: 13px;" rowspan="1" colspan="1">
<bold>Drugs&#x000a0;</bold>
</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 292.773px; height: 27px;" rowspan="1" colspan="1">Block synthesis of mutated TTR protein by mRNA silencing&#x000a0;</td>
                <td style="width: 125.226px; height: 27px;" rowspan="1" colspan="1">
<p>Patisiran&#x000a0;<xref ref-type="bibr" rid="article-137847.r64">[64]</xref>,&#x000a0;</p>
<p>Inotersen&#x000a0;<xref ref-type="bibr" rid="article-137847.r65">[65]</xref></p>
</td>
              </tr>
              <tr style="height: 60px;">
                <td style="width: 292.773px; height: 60px;" rowspan="1" colspan="1">Stabilize TTR tetramer to prevent tissue deposition&#x000a0;</td>
                <td style="width: 125.226px; height: 60px;" rowspan="1" colspan="1">
<p>Tafamidis <xref ref-type="bibr" rid="article-137847.r66">[66]</xref>,&#x000a0;</p>
<p>Diflusinal&#x000a0;<xref ref-type="bibr" rid="article-137847.r67">[67]</xref></p>
</td>
              </tr>
              <tr style="height: 56.5px;">
                <td style="width: 292.773px; height: 56.5px;" rowspan="1" colspan="1">Remove deposited amyloid fibrils&#x000a0;</td>
                <td style="width: 125.226px; height: 56.5px;" rowspan="1" colspan="1">
<p>Doxycycline and tauroursodeoxycholic acid (used in combination)</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The first two strategies described in the table above have a few pharmacological agents approved for clinical use by the US Food and Drug Administration (FDA). The third strategy of using doxycycline with&#x000a0;tauroursodeoxycholic acid is still being evaluated in clinical trials.<xref ref-type="bibr" rid="article-137847.r3">[3]</xref><xref ref-type="bibr" rid="article-137847.r57">[57]</xref></p>
        <table-wrap id="article-137847.table2" position="float" orientation="portrait">
          <table style="width: 551px;" border="1" cellspacing="1" cellpadding="8">
            <tbody>
              <tr>
                <td style="width: 133.203px;" rowspan="1" colspan="1">
<bold>Drugs</bold>
</td>
                <td style="width: 344.797px;" rowspan="1" colspan="1">
<bold>FDA status and Clinica use&#x000a0;</bold>
</td>
              </tr>
              <tr>
                <td style="width: 133.203px;" rowspan="1" colspan="1">
<p>Patisiran&#x000a0;(Onpattro)</p>
<p>&#x00026;</p>
<p>Inotersen&#x000a0;(Tegsedi)</p>
</td>
                <td style="width: 344.797px;" rowspan="1" colspan="1">
<p>- Not presently FDA approved for use in ATTR-CM.&#x000a0;</p>
<p>- FDA-approved for hATTR polyneuropathy (with or without cardiomyopathy)</p>
</td>
              </tr>
              <tr>
                <td style="width: 133.203px;" rowspan="1" colspan="1">
<p>Tafamidis (Vyndamax)</p>
<p>&#x00026;</p>
<p>Tafamidis meglumine (Vyndaqel)</p>
</td>
                <td style="width: 344.797px;" rowspan="1" colspan="1">FDA approved for ATTR-CM</td>
              </tr>
              <tr>
                <td style="width: 133.203px;" rowspan="1" colspan="1">Diflunisal</td>
                <td style="width: 344.797px;" rowspan="1" colspan="1">Not FDA approved. Still under clinical investigation.&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Tafamidis</bold>
</p>
        <p>Tafamidis and tafamidis meglumine received FDA approval in May 2019 for treating ATTR-CM. Tafamidis selectively binds to the thyroxine-binding sites of TTR. It stabilizes the tetrameric form and slows dissociating into monomers, reducing amyloid formation.[68] It works by reducing further ATTR deposition; it can slow disease progression but may not reverse it. Also, treatment with tafamidis should be started early in the disease process to see the clinical benefits.</p>
        <p>Tafamidis has demonstrated&#x000a0;a reduction in all-cause mortality and cardiovascular hospitalization in both hATTR-CM and wATTR-CM patients with heart failure of NYHA functional Classes I and II. In addition, its treatment has been shown to reduce the decline in functional capacity (six-minute walk test) and quality of life (Kansas City cardiomyopathy questionnaire). In approximately six months, functional improvement was seen, and mortality reduction took nearly two years.<xref ref-type="bibr" rid="article-137847.r68">[68]</xref><xref ref-type="bibr" rid="article-137847.r69">[69]</xref>&#x000a0;Based on these findings, the European Society of Cardiology has given a class 1B recommendation to use tafamidis in hATTR-CM and wATTR-CM patients with heart failure of&#x000a0;NYHA functional classes I and II.<xref ref-type="bibr" rid="article-137847.r70">[70]</xref></p>
        <p>The FDA-approved dose for tafamidis is 61 mg orally once daily, and for meglumine, it is 80 mg orally once daily.&#x000a0;</p>
        <p>Tafamidis is well tolerated. In the ATTR-ACT trial, 441 patients with ATTR-CM were&#x000a0;randomly assigned tafamidis 80 mg, 20 mg, and placebo in&#x000a0;a 2:1:2 ratio. Patients were followed for 30 months. The rate of adverse events was similar in the treatment and placebo groups.<xref ref-type="bibr" rid="article-137847.r71">[71]</xref>&#x000a0;</p>
        <p>
<bold>Organ Transplantation</bold>
</p>
        <p>A liver transplant can remove mutant TTR from circulation. It has previously been used to treat hATTR but cannot be used for wATTR.<xref ref-type="bibr" rid="article-137847.r72">[72]</xref>&#x000a0;Since the advent of TTR-specific&#x000a0;therapies, the need for liver transplants has dramatically reduced. Although theoretically, combined liver and heart transplants can be done in selected patients with both wATTR-CM and hATTR-CM, it is rarely seen in clinical practice as these patients are often of advanced age with poor long-term survival.<xref ref-type="bibr" rid="article-137847.r73">[73]</xref></p>
      </sec>
      <sec id="article-137847.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Light chain amyloid (AL) cardiomyopathy</p>
        <p>Other causes of&#x000a0;infiltrative&#x000a0;cardiomyopathy</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Cardiac hemochromatosis</p>
          </list-item>
          <list-item>
            <p>Fabry disease</p>
          </list-item>
          <list-item>
            <p>Mucopolysaccharidoses</p>
          </list-item>
        </list>
        <p>Hypertrophic cardiomyopathy</p>
      </sec>
      <sec id="article-137847.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>A gene-editing approach using&#x000a0;CRISPR-associated protein 9 is under development to treat hATTR. This approach hypothesizes that target DNA can be permanently modified. Thus, permanently silencing mutated TTR may treat hATTR.</p>
        <p>PRX-004 is being studied to treat ATTR amyloidosis. It is hypothesized to work by&#x000a0;removing ATTR deposits from the myocardium.</p>
      </sec>
      <sec id="article-137847.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Based on the threshold of troponin T ( &#x0003e;0.05 ng/ml) and Nt-proBNP (&#x0003e;3,000 pg/ml), Grogan et al. have described the&#x000a0;Mayo Clinic wATTR-CM staging system.<xref ref-type="bibr" rid="article-137847.r33">[33]</xref>&#x000a0;The system classifies the disease into 3 stages, which are defined as:</p>
        <table-wrap id="article-137847.table3" position="float" orientation="portrait">
          <table style="width: 449px;" border="1" cellspacing="1" cellpadding="8">
            <tbody>
              <tr>
                <td style="width: 45.5859px;" rowspan="1" colspan="1">Stage I</td>
                <td style="width: 333.414px;" rowspan="1" colspan="1">Both biomarker values are below the threshold</td>
              </tr>
              <tr>
                <td style="width: 45.5859px;" rowspan="1" colspan="1">Stage II</td>
                <td style="width: 333.414px;" rowspan="1" colspan="1">One of the 2 biomarker's values is above the threshold</td>
              </tr>
              <tr>
                <td style="width: 45.5859px;" rowspan="1" colspan="1">Stage III</td>
                <td style="width: 333.414px;" rowspan="1" colspan="1">Both biomarker values are above the threshold</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-137847.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Data suggest that survival in hATTR-CM is worse when compared to wATTR-CM. Mean survival in hATTR-CM (Val122lle) is approximately 2.5 years. hATTR patients with&#x000a0;isolated polyneuropathy with no heart involvement have a better prognosis with a mean survival of 8&#x000a0;to 10 years.<xref ref-type="bibr" rid="article-137847.r31">[31]</xref></p>
        <p>The median survival in wATTR is approximately 3.5 years, and it can&#x000a0;further be risk-stratified based on the Mayo Clinic wATTR-CM staging system. Stage I: 66 months;&#x000a0;Stage II: 42 months;&#x000a0;Stage III: 20 months.<xref ref-type="bibr" rid="article-137847.r33">[33]</xref></p>
        <p>The U.K. National Amyloidosis Center studied both hATTR and wATTR cohorts and used Nt-proBNP (&#x0003e;3000 pg/dl) and estimated glomerular filtration rate (&#x0003c;45 ml/min/1.73 m<sup>2</sup>). They reported a mean survival in hATTR-CM (Val122lle) of 29 months and wATTR of 49 months.&#x000a0;Interestingly, echocardiographic findings, including left ventricular mass, wall thickness, and degree of diastolic dysfunction, were not found to be an independent predictor of survival.<xref ref-type="bibr" rid="article-137847.r74">[74]</xref></p>
        <p>Technitium pyrophosphate scan can be used for prognosticating ATTR-CM as well. A heart to the contralateral chest uptake ratio&#x000a0;of 1.6 or greater has poorer&#x000a0;5-year outcomes.<xref ref-type="bibr" rid="article-137847.r54">[54]</xref></p>
      </sec>
      <sec id="article-137847.s14" sec-type="Complications">
        <title>Complications</title>
        <p>If untreated, ATTR-CM can cause progressive worsening heart failure, arrhythmias, and conduction system diseases, which&#x000a0;can cause sudden cardiac death due to fatal arrhythmias or complete heart block. In addition, the functional capacity and the quality of life deteriorate exponentially with every heart failure exacerbation and subsequent hospitalization.&#x000a0;</p>
        <p>Tafamidis, which is used for the treatment of ATTR-CM, is well tolerated. However, in clinical trials, the rate of adverse events was similar&#x000a0;in tafamidis and placebo groups.<xref ref-type="bibr" rid="article-137847.r71">[71]</xref></p>
      </sec>
      <sec id="article-137847.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>
<bold>What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?</bold>
</p>
        <p>Transthyretin amyloid cardiomyopathy is caused by the deposition of an abnormally folded protein called transthyretin. Transthyretin is a naturally occurring protein in the human body that helps&#x000a0;transport the thyroid hormone in the bloodstream.</p>
        <p>This abnormally folded transthyretin protein can be deposited in various organs and tissues in the body, including nerves, the heart, the kidneys, and the gastrointestinal tract. An abnormal buildup of transthyretin amyloid protein in heart muscle stiffens it,&#x000a0;eventually leading to congestive heart failure.</p>
        <p>
<bold>Are There Different Types of ATTR-CM?</bold>
</p>
        <p>There are two types of ATTR-CM: hereditary (hATTR-CM) and wild type (wATTR-CM). hATTR-CM is a genetic disease caused by a genetic mutation in the transthyretin gene. wATTR-CM is an aging disease in which normal transthyretin protein becomes structurally unstable and gets deposited in the heart. hATTR-CM can occur in younger people (50s to 60s), whereas wATTR usually occurs in older people (late 70s to 80s).&#x000a0;&#x000a0;</p>
        <p>
<bold>What Are Some Common Clinical Symptoms of ATTR-CM?</bold>
</p>
        <p>Patients may develop heart failure, which can present as reduced exercise capacity, shortness of breath, and swelling in the legs. Patients may have a recurrent exacerbation of shortness of breath and difficulty breathing, requiring frequent emergency room and hospitalization. Atrial fibrillation is often seen. Patients often have lightheadedness, dizziness, and loss of consciousness due to slow heart rate and brief heartbeat pauses. This may be due to slow heart rate and transient pauses of the heartbeat. Patients often report intolerance (low blood pressure, postural hypotension) to traditional medications used for heart failure management, including beta-blockers and ACE inhibitors or angiotensin receptor blockers. &#x000a0;</p>
        <p>
<bold>Is There Any Treatment Available for ATTR-CM?</bold>
</p>
        <p>Few new drugs and treatment strategies have emerged in recent years, and many are still under clinical review. However, in &#x000a0;2019, the US FDA approved tafamidis for clinical use in ATTR-CM. Tafamidis is an oral medication that is used in once a day formulation. Tafamidis can prevent further disease progression but, unfortunately, cannot reverse the disease process. Therefore, early identification and treatment of&#x000a0;ATTR-CM are&#x000a0;advised.</p>
      </sec>
      <sec id="article-137847.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>ATTR-CM is emerging as an essential clinical entity in the realm of heart failure with preserved ejection fraction. Real-world clinical data have demonstrated an increased prevalence of ATTR-CM than previously perceived. Which improving novel non-invasive imaging techniques, clinicians can now facilitate early diagnosis of ATTR-CM. With the advent of effective therapeutic options for ATTR-CM, it is now possible to improve outcomes in these patients. However, as these therapies cannot reverse the disease process and can only prevent further progression,&#x000a0;early identification is paramount for them to be most effective.&#x000a0;</p>
        <p>Primary care physicians and general cardiologists should understand the disease process and pathophysiology of ATTR-CM. They should look for clinical cues of ATTR-CM and should screen patients who fit the clinical picture. Novel non-invasive cardiac imaging like cardiac MRI and bone avid scintigraphy may have an essential role in diagnosing ATTR-CM. Echocardiogram with strain imaging has also emerged as an efficient screening tool. Radiologists and cardiologists specializing in cardiac imaging&#x000a0;should get more familiar with imaging patterns and findings of ATTR-CM.</p>
      </sec>
      <sec id="article-137847.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137847">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/transthyretin-amyloid-cardiomyopathy-attr-cm/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=137847">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/137847/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=137847">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-137847.s18">
        <fig id="article-137847.image.f1" position="float" orientation="portrait">
          <caption>
            <p>AL: Light chain amyloid; ATTR: Transthyretin amyloid; Wt: wild type; Hr: Hereditary type (genetic) Contributed by Anubhav Jain, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cardiac__amyloid__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-137847.s19">
        <fig id="article-137847.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Echocardiogram of patient with ATTR-CM showing moderate to severe concentric left ventricular hypertrophy, small left ventricular cavity and enlarged left atrium. Notice increased echogenicity of myocardium suggestive of infiltrative process. Also notice that there is preserved systolic motion in apex segments compared to basal segments. Contributed by Anubhav Jain, MD</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ATTR__CM__patient__with__severe__concentric__LVH.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-137847.s20">
        <title>References</title>
        <ref id="article-137847.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-Naharro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiac amyloidosis.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>18</volume>
            <issue>Suppl 2</issue>
            <fpage>s30</fpage>
            <page-range>s30-s35</page-range>
            <pub-id pub-id-type="pmid">29700090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubrey</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Amyloid diseases of the heart: assessment, diagnosis, and referral.</article-title>
            <source>Heart</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>97</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-84</page-range>
            <pub-id pub-id-type="pmid">21148582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>11</day>
            <volume>73</volume>
            <issue>22</issue>
            <fpage>2872</fpage>
            <page-range>2872-2891</page-range>
            <pub-id pub-id-type="pmid">31171094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AbouEzzeddine</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Fayyaz</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Askew</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McKie</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Borlaug</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Chareonthaitawee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>JAMA Cardiol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>1267</fpage>
            <page-range>1267-1274</page-range>
            <pub-id pub-id-type="pmid">34431962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Colon</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lashuel</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCutchen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Miroy</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.</article-title>
            <source>Adv Protein Chem</source>
            <year>1997</year>
            <volume>50</volume>
            <fpage>161</fpage>
            <page-range>161-81</page-range>
            <pub-id pub-id-type="pmid">9338081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mar</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franquinho</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Aboard transthyretin: From transport to cleavage.</article-title>
            <source>IUBMB Life</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>429</fpage>
            <page-range>429-35</page-range>
            <pub-id pub-id-type="pmid">20503435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornwell</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Sletten</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>1988</year>
            <month>Jul</month>
            <day>29</day>
            <volume>154</volume>
            <issue>2</issue>
            <fpage>648</fpage>
            <page-range>648-53</page-range>
            <pub-id pub-id-type="pmid">3135807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sletten</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cornwell</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Fibril in senile systemic amyloidosis is derived from normal transthyretin.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>7</issue>
            <fpage>2843</fpage>
            <page-range>2843-5</page-range>
            <pub-id pub-id-type="pmid">2320592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
            </person-group>
            <article-title>THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-76</page-range>
            <pub-id pub-id-type="pmid">23193944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pomerance</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Senile cardiac amyloidosis.</article-title>
            <source>Br Heart J</source>
            <year>1965</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>711</fpage>
            <page-range>711-8</page-range>
            <pub-id pub-id-type="pmid">5829755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinney</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dungu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banypersad</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sattianayagam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Venner</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Wassef</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Senile systemic amyloidosis: clinical features at presentation and outcome.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2013</year>
            <month>Apr</month>
            <day>22</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>e000098</fpage>
            <pub-id pub-id-type="pmid">23608605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rozenbaum</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Large</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhambri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Doornewaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Masri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review.</article-title>
            <source>Cardiol Ther</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-159</page-range>
            <pub-id pub-id-type="pmid">33877591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Glaudemans</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guidalotti</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Flatman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vonberg</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hutt</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hazenberg</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Jun</month>
            <day>14</day>
            <volume>133</volume>
            <issue>24</issue>
            <fpage>2404</fpage>
            <page-range>2404-12</page-range>
            <pub-id pub-id-type="pmid">27143678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindmark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pilebro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindqvist</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.</article-title>
            <source>ESC Heart Fail</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>745</fpage>
            <page-range>745-749</page-range>
            <pub-id pub-id-type="pmid">33205581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gallego-Delgado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guzzo-Merello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Haro-Del Moral</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Cobo-Marcos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lara-Pezzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alonso-Pulpon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garcia-Pavia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Oct</month>
            <day>07</day>
            <volume>36</volume>
            <issue>38</issue>
            <fpage>2585</fpage>
            <page-range>2585-94</page-range>
            <pub-id pub-id-type="pmid">26224076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornwell</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pitk&#x000e4;nen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation.</article-title>
            <source>Am J Med</source>
            <year>1983</year>
            <month>Oct</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>618</fpage>
            <page-range>618-23</page-range>
            <pub-id pub-id-type="pmid">6624768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammed</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Mirzoyev</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Redfield</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.</article-title>
            <source>JACC Heart Fail</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-22</page-range>
            <pub-id pub-id-type="pmid">24720917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casta&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narotsky</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khalique</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Morgenstern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiuzan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nazif</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vahl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kodali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.</article-title>
            <source>Eur Heart J</source>
            <year>2017</year>
            <month>Oct</month>
            <day>07</day>
            <volume>38</volume>
            <issue>38</issue>
            <fpage>2879</fpage>
            <page-range>2879-2887</page-range>
            <pub-id pub-id-type="pmid">29019612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witteles</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Gospodinova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garcia-Pavia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.</article-title>
            <source>JACC Heart Fail</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>709</fpage>
            <page-range>709-716</page-range>
            <pub-id pub-id-type="pmid">31302046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lane</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Naharro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hutt</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strehina</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Caringal-Galima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharpley</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachchithanantham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drage</surname>
                <given-names>EPS</given-names>
              </name>
              <name>
                <surname>Jenner</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertolli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Calleja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jul</month>
            <day>02</day>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-26</page-range>
            <pub-id pub-id-type="pmid">31109193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grodin</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges.</article-title>
            <source>Heart Fail Rev</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-45</page-range>
            <pub-id pub-id-type="pmid">32794090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buxbaum</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.</article-title>
            <source>Genet Med</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>733</fpage>
            <page-range>733-742</page-range>
            <pub-id pub-id-type="pmid">28102864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connors</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salinaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Seldin</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Jan</month>
            <day>19</day>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-90</page-range>
            <pub-id pub-id-type="pmid">26660282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donnellan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wazni</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elshazly</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saliba</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kanj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vakamudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Baranowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cantillon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dresing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jaber</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies.</article-title>
            <source>JACC Clin Electrophysiol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>1118</fpage>
            <page-range>1118-1127</page-range>
            <pub-id pub-id-type="pmid">32972546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subbiah</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ventricular Arrhythmias in Cardiac Amyloidosis: A Review of Current Literature.</article-title>
            <source>Clin Med Insights Cardiol</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>1179546820963055</fpage>
            <pub-id pub-id-type="pmid">33088185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>20</day>
            <volume>68</volume>
            <issue>12</issue>
            <fpage>1323</fpage>
            <page-range>1323-41</page-range>
            <pub-id pub-id-type="pmid">27634125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellikka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tajik</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.</article-title>
            <source>Arch Intern Med</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>148</volume>
            <issue>3</issue>
            <fpage>662</fpage>
            <page-range>662-6</page-range>
            <pub-id pub-id-type="pmid">3341867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gonzalez-Lopez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Botcher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Youngstein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachchithanantham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.</article-title>
            <source>Eur Heart J</source>
            <year>2017</year>
            <month>Jun</month>
            <day>21</day>
            <volume>38</volume>
            <issue>24</issue>
            <fpage>1905</fpage>
            <page-range>1905-1908</page-range>
            <pub-id pub-id-type="pmid">28605421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vrana</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gamez</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Madden</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Theis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bergen</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Dec</month>
            <day>03</day>
            <volume>114</volume>
            <issue>24</issue>
            <fpage>4957</fpage>
            <page-range>4957-9</page-range>
            <pub-id pub-id-type="pmid">19797517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ciliberti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pastorelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biagini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coccolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bacchi-Reggiani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sangiorgi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferlini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cavo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zamagni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fonte</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salinaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Musca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Branzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perlini</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Sep</month>
            <day>29</day>
            <volume>120</volume>
            <issue>13</issue>
            <fpage>1203</fpage>
            <page-range>1203-12</page-range>
            <pub-id pub-id-type="pmid">19752327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin (TTR) cardiac amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Sep</month>
            <day>04</day>
            <volume>126</volume>
            <issue>10</issue>
            <fpage>1286</fpage>
            <page-range>1286-300</page-range>
            <pub-id pub-id-type="pmid">22949539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pilebro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>N&#x000e4;slund</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindqvist</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.</article-title>
            <source>Ups J Med Sci</source>
            <year>2016</year>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">26849806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klarich</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Maleszewski</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Natural History of Wild-Type Transthyretin&#x000a0;Cardiac Amyloidosis and&#x000a0;Risk Stratification Using a Novel&#x000a0;Staging System.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>68</volume>
            <issue>10</issue>
            <fpage>1014</fpage>
            <page-range>1014-20</page-range>
            <pub-id pub-id-type="pmid">27585505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>AbouEzzeddine</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kushwaha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clavell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.</article-title>
            <source>Transplantation</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>1909</fpage>
            <page-range>1909-1913</page-range>
            <pub-id pub-id-type="pmid">29677073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Lousada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cristina Quarta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.</article-title>
            <source>Circ Heart Fail</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e006075</fpage>
            <pub-id pub-id-type="pmid">31480867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mints</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Doros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.</article-title>
            <source>ESC Heart Fail</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>772</fpage>
            <page-range>772-779</page-range>
            <pub-id pub-id-type="pmid">29916559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>John</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Arrhythmias in Cardiac Amyloidosis.</article-title>
            <source>J Innov Card Rhythm Manag</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>3051</fpage>
            <page-range>3051-3057</page-range>
            <pub-id pub-id-type="pmid">32477799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Klarich</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>May</month>
            <day>12</day>
            <volume>119</volume>
            <issue>18</issue>
            <fpage>2490</fpage>
            <page-range>2490-7</page-range>
            <pub-id pub-id-type="pmid">19414641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakagawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sekijima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tojo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshinaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doden</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.</article-title>
            <source>Amyloid</source>
            <year>2016</year>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-63</page-range>
            <pub-id pub-id-type="pmid">26852880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis.</article-title>
            <source>Ups J Med Sci</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-8</page-range>
            <pub-id pub-id-type="pmid">24620715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geller</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Mirto</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Sep</month>
            <day>12</day>
            <volume>318</volume>
            <issue>10</issue>
            <fpage>962</fpage>
            <page-range>962-963</page-range>
            <pub-id pub-id-type="pmid">28898370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Al-Sergani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mourad</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tabbaa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.</article-title>
            <source>Tex Heart Inst J</source>
            <year>2005</year>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-84</page-range>
            <pub-id pub-id-type="pmid">16107109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gertz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Beir&#x000e3;o</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Comenzo</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Lousada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.</article-title>
            <source>BMC Fam Pract</source>
            <year>2020</year>
            <month>Sep</month>
            <day>23</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>198</fpage>
            <pub-id pub-id-type="pmid">32967612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mussinelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salinaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alogna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boldrini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raimondi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Musca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perlini</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.</article-title>
            <source>Ann Noninvasive Electrocardiol</source>
            <year>2013</year>
            <month>May</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-80</page-range>
            <pub-id pub-id-type="pmid">23714086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dungu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sattianayagam</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pinney</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Banypersad</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.</article-title>
            <source>Am Heart J</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>164</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-9</page-range>
            <pub-id pub-id-type="pmid">22795285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Glockner</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Araoz</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bellavia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tajik</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-64</page-range>
            <pub-id pub-id-type="pmid">20159642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagourelias</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Mirea</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Duchenne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Cleemput</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delforge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bogaert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuznetsova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Voigt</surname>
                <given-names>JU</given-names>
              </name>
            </person-group>
            <article-title>Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters.</article-title>
            <source>Circ Cardiovasc Imaging</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>e005588</fpage>
            <pub-id pub-id-type="pmid">28298286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Uraizee</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kruger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gagliardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Milandri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>May</month>
            <day>06</day>
            <volume>129</volume>
            <issue>18</issue>
            <fpage>1840</fpage>
            <page-range>1840-9</page-range>
            <pub-id pub-id-type="pmid">24563469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2016</year>
            <month>Jun</month>
            <day>07</day>
            <volume>16</volume>
            <fpage>129</fpage>
            <pub-id pub-id-type="pmid">27267362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-Naharro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Treibel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Abdel-Gadir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bulluck</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zumbo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hutt</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rosmini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kellman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Magnetic Resonance in Transthyretin&#x000a0;Cardiac Amyloidosis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>25</day>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>466</fpage>
            <page-range>466-477</page-range>
            <pub-id pub-id-type="pmid">28728692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvalho</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Erthal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis.</article-title>
            <source>Magn Reson Imaging Clin N Am</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-463</page-range>
            <pub-id pub-id-type="pmid">31279449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dungu</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Valencia</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pinney</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>CMR-based differentiation of AL and ATTR cardiac amyloidosis.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-42</page-range>
            <pub-id pub-id-type="pmid">24412186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stats</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis.</article-title>
            <source>Cardiovasc Pathol</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>413</fpage>
            <page-range>413-7</page-range>
            <pub-id pub-id-type="pmid">27469499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haq</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narotsky</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Morgenstern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pozniakoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.</article-title>
            <source>JAMA Cardiol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>1</volume>
            <issue>8</issue>
            <fpage>880</fpage>
            <page-range>880-889</page-range>
            <pub-id pub-id-type="pmid">27557400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pozniakoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Deslisle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Latif</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.</article-title>
            <source>Circ Cardiovasc Imaging</source>
            <year>2013</year>
            <month>Mar</month>
            <day>01</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-201</page-range>
            <pub-id pub-id-type="pmid">23400849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phull</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanchorawala</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Doros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sarosiek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).</article-title>
            <source>Amyloid</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-67</page-range>
            <pub-id pub-id-type="pmid">29424556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shorer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramgobin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Golamari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cardiac amyloidosis-A review of current literature for the practicing physician.</article-title>
            <source>Clin Cardiol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>322</fpage>
            <page-range>322-331</page-range>
            <pub-id pub-id-type="pmid">33595871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhuiyan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Helmke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Packman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).</article-title>
            <source>Circ Heart Fail</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-8</page-range>
            <pub-id pub-id-type="pmid">21191093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.</article-title>
            <source>Chest</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>618</fpage>
            <page-range>618-20</page-range>
            <pub-id pub-id-type="pmid">8339658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Am</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melduni</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ammash</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pislaru</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Egbe</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nkomo</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Direct Current Cardioversion of Atrial&#x000a0;Arrhythmias in Adults With Cardiac&#x000a0;Amyloidosis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>589</fpage>
            <page-range>589-597</page-range>
            <pub-id pub-id-type="pmid">30732713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epstein</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>DiMarco</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ellenbogen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gettes</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gillinov</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gregoratos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Silka</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Buller</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hiratzka</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Lytle</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tarkington</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices)</collab>
              <collab>American Association for Thoracic Surgery</collab>
              <collab>Society of Thoracic Surgeons</collab>
            </person-group>
            <article-title>ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2008</year>
            <month>May</month>
            <day>27</day>
            <volume>51</volume>
            <issue>21</issue>
            <fpage>e1</fpage>
            <page-range>e1-62</page-range>
            <pub-id pub-id-type="pmid">18498951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Dengler</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hegenbart</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schonland</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sack</surname>
                <given-names>FU</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katus</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.</article-title>
            <source>Heart Rhythm</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-40</page-range>
            <pub-id pub-id-type="pmid">18242546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varr</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Zarafshar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liedtke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lafayette</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schrier</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.</article-title>
            <source>Heart Rhythm</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>158</fpage>
            <page-range>158-62</page-range>
            <pub-id pub-id-type="pmid">24121001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buades</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pouget</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Conceicao</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Waddington-Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bettencourt</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Vaishnaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gollob</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2015</year>
            <month>Sep</month>
            <day>04</day>
            <volume>10</volume>
            <fpage>109</fpage>
            <pub-id pub-id-type="pmid">26338094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarlas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lovley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCausland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vera-Llonch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Concei&#x000e7;&#x000e3;o</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Waddington-Cruz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.</article-title>
            <source>Neurol Ther</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>865</fpage>
            <page-range>865-886</page-range>
            <pub-id pub-id-type="pmid">34355354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <collab>ATTR-ACT Study Investigators</collab>
            </person-group>
            <article-title>Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).</article-title>
            <source>Circ Heart Fail</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28611125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sekijima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heneghan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gorevic</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Litchy</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Wiesman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nordh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lozza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson-Papp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rybin</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Bisbee</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seldin</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dyck</surname>
                <given-names>PJ</given-names>
              </name>
              <collab>Diflunisal Trial Consortium</collab>
            </person-group>
            <article-title>Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Dec</month>
            <day>25</day>
            <volume>310</volume>
            <issue>24</issue>
            <fpage>2658</fpage>
            <page-range>2658-67</page-range>
            <pub-id pub-id-type="pmid">24368466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Waddington-Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Barsdorf</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <collab>ATTR-ACT Study Investigators</collab>
            </person-group>
            <article-title>Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>13</day>
            <volume>379</volume>
            <issue>11</issue>
            <fpage>1007</fpage>
            <page-range>1007-1016</page-range>
            <pub-id pub-id-type="pmid">30145929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garcia-Pavia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-285</page-range>
            <pub-id pub-id-type="pmid">33070419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonagh</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Baumbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x0010c;elutkien&#x00117;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chioncel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>JGF</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Crespo-Leiro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Farmakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heymans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jaarsma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jankowska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lainscak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>CSP</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mindham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muneretto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Francesco Piepoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kathrine Skibelund</surname>
                <given-names>A</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.</article-title>
            <source>Eur Heart J</source>
            <year>2021</year>
            <month>Sep</month>
            <day>21</day>
            <volume>42</volume>
            <issue>36</issue>
            <fpage>3599</fpage>
            <page-range>3599-3726</page-range>
            <pub-id pub-id-type="pmid">34447992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rozenbaum</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhambri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heeg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.</article-title>
            <source>Eur Heart J Qual Care Clin Outcomes</source>
            <year>2022</year>
            <month>Aug</month>
            <day>17</day>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-538</page-range>
            <pub-id pub-id-type="pmid">33895806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vollmar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hoppe-Lotichius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barreiros</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emrich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Geber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weyer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mittler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birklein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Galle</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.</article-title>
            <source>Transpl Int</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1207</fpage>
            <page-range>1207-1215</page-range>
            <pub-id pub-id-type="pmid">30091268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sousa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monohan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grigorian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guglin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heart transplantation in cardiac amyloidosis.</article-title>
            <source>Heart Fail Rev</source>
            <year>2017</year>
            <month>May</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-327</page-range>
            <pub-id pub-id-type="pmid">28281017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137847.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Martinez-Naharro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gonzalez-Lopez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>A new staging system for cardiac transthyretin amyloidosis.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Aug</month>
            <day>07</day>
            <volume>39</volume>
            <issue>30</issue>
            <fpage>2799</fpage>
            <page-range>2799-2806</page-range>
            <pub-id pub-id-type="pmid">29048471</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
